Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Fiche publication
Date publication
septembre 2009
Journal
World journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr LADOIRE Sylvain
Tous les auteurs :
Ghiringhelli F, Guiu B, Chauffert B, Ladoire S
Lien Pubmed
Résumé
To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma.
Mots clés
Aged, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Bevacizumab, Camptothecin, administration & dosage, Carcinoma, drug therapy, Colorectal Neoplasms, drug therapy, Female, Fluorouracil, administration & dosage, Humans, Male, Middle Aged, Pilot Projects, Sirolimus, administration & dosage, Treatment Outcome
Référence
World J. Gastroenterol.. 2009 Sep;15(34):4278-83